反应详情

A mixture of diphenylmethyl 7-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetamido]-3-(3-iodo-1-propen-1-yl)-3-cephem-4-carboxylate (IX-1) (E, 716 mg, 1 mmole) and 3-(t-butyloxycarbonylaminomethyl)pyridine (516 mg, 2 mmoles) in DMSO (2 ml) was stirred at ambient temperature for 30 minutes. The mixture was poured into ethyl acetate (200 ml), and the precipitate was collected by filtration, washed well with ethyl acetate and dried. A mixture of the quaternized salt (500 mg), sodium bisulfite (50 mg) in HCOOH (5 ml) was stirred at 40°-50° C. for 80 minutes and evaporated to dryness under reduced pressure. The residual solid was dissolved in water (40 ml), and the mixture was neutralized with NaHCO3. Insoluble material was filtered off, and the filtrate was chromatographed on a reverse phase column (packing of PrepPAK-500/C18 cartridge, 100 ml), eluting with water, 5%, 10%, 20% and 30% aqueous CH3OH, successively. The fractions containing the desired compound were combined, evaporated and lyophilized to provide 10 mg (1.8%) of the title compound (I-1I) (E) as a tan powder.

1. filtrationthe precipitate was collected by filtration
2. washwashed well with ethyl acetate
3. customdried
4. additionA mixture of the quaternized salt (500 mg), sodium bisulfite (50 mg) in HCOOH (5 ml)
5. stirringwas stirred at 40°-50° C. for 80 minutes
6. customevaporated to dryness under reduced pressure
7. dissolutionThe residual solid was dissolved in water (40 ml)
8. filtrationInsoluble material was filtered off
9. customthe filtrate was chromatographed on a reverse phase column (packing of PrepPAK-500/C18 cartridge, 100 ml),
10. washeluting with water, 5%, 10%, 20% and 30% aqueous CH3OH
11. additionThe fractions containing the desired compound
12. customevaporated